Business Model Breakdown
How Skye Bioscience Inc Makes Money
SKYE
Market Cap
$25M
Profit Margin
-3.6%
Employees
16
The Short Version
Skye Bioscience is a clinical-stage pharmaceutical company focused on developing novel cannabinoid-derived therapeutics for unmet medical needs. Its primary focus is on SBI-100, which is currently in Phase 2a clinical trials for the treatment of glaucoma, with potential expansion into obesity and related metabolic conditions. The company currently generates no revenue and relies entirely on external financing to fund its expensive research and development activities, with future revenue expected from drug sales upon regulatory approval or from licensing agreements with larger pharmaceutical partners.
Where the Revenue Comes From
Future Drug Sales (0% currently)
Future Licensing/Partnership Royalties (0% currently)
Who buys: Future patients suffering from glaucoma, obesity, and related conditions; potential pharmaceutical partners for drug development and commercialization.
Why It Works (Competitive Advantages)
- ✔Novel cannabinoid-derived therapeutic approach (SBI-100) as a potential new mechanism for glaucoma and other indications (obesity).
- ✔Proprietary IP surrounding its lead compounds and formulation.
Economic Moat: None (Intangible Assets/IP (potential, if clinical success translates to market exclusivity))
What Our Analysis Says
DVR Score as of June 3, 2026
Skye Bioscience remains a deeply speculative investment. While clinical execution for its cannabinoid-derived therapeutic has shown positive safety data for Cohort 1 and progress to Cohort 2, its financial health has materially deteriorated. The company reported a wider net loss and significant cash burn in Q1 2026, leading to a critical Nasdaq deficiency notice due to insufficient stockholders' equity. This poses an immediate delisting risk. The authorized share increase signals further significant dilution is likely needed. The scientific premise offers high reward potential, especially if the obesity target is pursued alongside glaucoma, but the severe financial distress, delisting threat, and urgent capital needs create an exceptionally high-risk profile. The path to 10x growth is contingent on overcoming these imminent financial and regulatory hurdles, which are now more severe than previously assessed.